Filtered By:
Infectious Disease: Tuberculosis
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 482 results found since Jan 2013.
Dysregulation of Immunity in Pulmonary Fibrosis is Associated with Increased Myeloid-specific Triggering Receptor-1 and Transforming Growth Factor-beta1 Expression
In this study, the expression of triggering receptor expressed on myeloid cells-1 (TREM-1) as a stimulator for the production of TGF-β1 and also CD4+CD25+Foxp3+ regulatory cells were investigted in FP patients. Sixteen UIP, 14 NSIP and 4 pulmonary fibrosis following Mycobacterium tuberculosis (TB) infection patients, were compared with 12 healthy controls. The frequency of blood CD14+TGF-β1+ and CD14+TREM1+-gated monocytes and CD4+CD25+Foxp3+ regulatory T cells (Treg), as well as the plasma levels of TGF-β1 and IL‑10 were measured. Fibrosis patients compared to healthy controls had a greater frequency of CD14+TGF-β1+...
Source: Iranian Journal of Allergy, Asthma and Immunology - April 1, 2023 Category: Allergy & Immunology Authors: Shima Rasouli Jalal Heshmatnia Nariman Mosaffa Majid Marjani Esmaeil Mortaz Source Type: research
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Drug Patch Testing in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review
CONCLUSION: Published reports suggest that PT in SJS/TEN is useful and safe. AEDs have been tested most frequently and show the highest positivity rate. There is a critical need for large-scale studies with standardized methodology to obtain reproducible data on PT in SJS/TEN.PMID:36649833 | DOI:10.1016/j.anai.2023.01.006
Source: Annals of Allergy, Asthma and Immunology - January 17, 2023 Category: Allergy & Immunology Authors: Danielle E Novack Melinda Braskett Scott D Worswick Brandon L Adler Source Type: research
Dr. Anthony Fauci Is Stepping Down. Here ’s His Advice For His Successor
After Dr. Anthony Fauci steps down as head of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to President Biden on Dec. 31, he’ll leave behind a long and storied career. Ahead of his last day, he spoke to TIME from his office at the National Institutes of Health about what’s next for him—and his advice for whoever fills his shoes.
This interview has been edited and condensed for clarity.
TIME: You’re leaving your leadership positions in the federal government, but you aren’t retiring. What are you calling the next stage in your career?
[time-brightc...
Source: TIME: Health - December 20, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Indoor Urban Environment and Conventional Risk Factors for Pediatric Tuberculosis Among 1 –12 Years Old Children in a Megacity in Pakistan: A Matched Case–Control Study
Pediatric Allergy, Immunology, and Pulmonology,Volume 35, Issue 4, Page 158-165, December 2022.
Source: Pediatric, Allergy, Immunology, and Pulmonology - December 15, 2022 Category: Respiratory Medicine Authors: Ambreen Sahito Zafar Fatmi Muhammad Masood Kadir Fehmina Arif Source Type: research
Infant BCG Vaccine Protects Only Those Under Age 5 Years Infant BCG Vaccine Protects Only Those Under Age 5 Years
Although the BCG vaccine may keep severe forms of tuberculosis, meningitis, and miliary tuberculosis at bay, its efficacy and effectiveness against pulmonary tuberculosis are low.Medscape Medical News
Source: Medscape Allergy Headlines - December 5, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
Utility of the provocation coupled with the drug reintroduction test in the diagnosis of a hypersensitivity reaction to fixed-dose combination (FDC) of anti-TB drugs
Conclusion: Diagnosis tests for a hypersensitivity reaction to FDC of anti-TB drugs are codified. In the absence of drug atopy tests, provocation coupled with reintroduction test find are usefull for the diagnosis of the incriminated molecule.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Sana, A., Asma, O., Rahma, B. J., Wafa, B., Asma, K., Amani, K., Imen, G., Ahmed, A., Abdelaziz, H. Tags: 10.02 - Tuberculosis and non-tuberculous mycobacterial diseases Source Type: research
Association of tuberculosis infection with asthma in a european multinational cohort
Conclusion: Our study showed that TB infection was associated with asthma, in particular non-allergic asthma. Longitudinal analyses are needed to further explore these results.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Gyawali, S., Lopez Cervantes, J. P., Mustafa, T., Svanes, C., Shigdel, R. Tags: 06.01 - Epidemiology Source Type: research
Molecules, Vol. 27, Pages 8316: Pharmacological and Clinical Efficacy of Picrorhiza kurroa and Its Secondary Metabolites: A Comprehensive Review
This study comprehensively evaluated the ethnopharmacological efficacy, phytochemistry, pharmacological activity, dose, and toxicity of P. kurroa. This review provides comprehensive insights into this traditional medication for future research and therapeutic application. The purpose of this review article was to determine the pharmacological effects of P. kurroa on a variety of disorders. P. kurroa may be a natural alternative to the standard treatment for eradicating newly evolving diseases. This study is intended as a resource for future fundamental and clinical investigations.
Source: Molecules - November 29, 2022 Category: Chemistry Authors: Tahani M. Almeleebia Abdulrhman Alsayari Shadma Wahab Tags: Review Source Type: research
Management of type 1 immediate hypersensitivity reactions to antituberculosis drug: succesful desensitization
In this study, it was aimed to investigate the prevalence of type 1 hypersensitivity reaction under tuberculosis treatment and the management of hypersensitivity.
Source: Allergy, Asthma and Clinical Immunology - November 21, 2022 Category: Allergy & Immunology Authors: Zeynep Yegin Katran, İsmet Bulut, Aylin Babalik and Metin Keren Tags: Research Source Type: research
Autoimmune and autoinflammatory manifestations in inborn errors of immunity
Purpose of review
Autoimmune and inflammatory complications have been shown to arise in all age groups and across the spectrum of inborn errors of immunity (IEI). This review aims to highlight recent ground-breaking research and its impact on our understanding of IEI.
Recent findings
Three registry-based studies of unprecedented size revealed the high prevalence of autoimmune, inflammatory and malignant complications in IEI. Two novel IEI were discovered: an autoinflammatory relopathy, cleavage-resistant RIPK1-induced autoinflammatory syndrome, as well as an inheritable phenocopy of PD-1 blockade-associated comp...
Source: Current Opinion in Allergy and Clinical Immunology - November 4, 2022 Category: Allergy & Immunology Tags: PRIMARY IMMUNE DEFICIENCY DISEASE: Edited by M. Teresa de la Morena and Stephen Jolles Source Type: research
Global Tuberculosis Cases, Deaths Rise During COVID Pandemic Global Tuberculosis Cases, Deaths Rise During COVID Pandemic
This is the first time the number of tuberculosis cases and drug-resistant tuberculosis cases has gone up in a number of years, the World Health Organization said.WebMD Health News
Source: Medscape Allergy Headlines - October 28, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
U.S. weighs crackdown on experiments that could make viruses more dangerous
.news-article__hero--featured .parallax__element{ object-position: 50% 40%; -o-object-position: 50% 40%; } .scroll-wrapper { overflow-x: auto; } .scroll-wrapper .news-article__figure__image{ width: 2680px; max-width: none; padding-bottom: .75rem; } .scroll-fade-before, .scroll-fade-after { position: absolute; width: 1.5rem; transition-duration: .1s; opacity: 1; } .scroll-fade-before { left: 1rem; /*margin-left: -1px;*/ background: linear-gradient(90deg, #fff, #fff 35%, hsla(0, 0%, 100%, 0)); } .scroll-fade-after { right: 1rem; /*margin-right: -1px;*/ background: linear-gradient(270deg, #fff, #fff 35%, hsla(0,...
Source: ScienceNOW - October 19, 2022 Category: Science Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
